周四，Laboratory Corp（NYSE: LH）报告其2024年第四季度调整后的每股收益为3.45美元，高于去年同期的3.30美元，超出市场预期的3.39美元。
销售额同比增长9.8%，达到33.3亿美元，几乎与市场预期的33.1亿美元一致。
销售额的增长归因于有机收入增长5.4%，收购和剥离净影响4%，以及外汇换算影响0.3%。
Labcorp董事长兼首席执行官Adam Schechter表示：“2024年，Labcorp凭借有机和非有机增长实现了卓越的业绩……此外，我们在包括肿瘤学、女性健康、神经病学和自身免疫性疾病等关键高增长领域加强了存在。2025年，我们有望在诊断实验室和生物制药实验室服务领域实现强劲增长和利润率扩张……”
调整后的季度运营收入为423.2百万美元，占收入的12.7%，而上一年同期为394.9百万美元，占收入的13%。
William Blair分析师Andrew F. Brackmann表示：“我们继续相信，Labcorp的基础业务稳固，诊断部门受益于有利的宏观经济因素，BLS部门在中心实验室内实现稳定增长（尽管在艰难的比较下有所放缓），早期开发重回增长轨道。”
这使得该股票在2025年具有稳定的指导性，并有可能在公司动能持续时获得收益。
William Blair重申“表现优异”评级。
指导意见：LabCorp预计2025年调整后的每股收益为15.60-16.40美元，高于市场预期的16.0美元。预计2025年销售额为139亿-141亿美元，高于市场预期的138亿美元。
该指导意见包括2025年诊断实验室销售额增长6.5%-7.7%，生物制药实验室服务销售额增长3.0%-5.0%。
股票价格动态:截至周四最后一次检查，Laboratory股票下跌0.92%，至247.68美元。
以上内容来自Benzinga Earnings专栏，原文如下：
Thursday, Laboratory Corp (NYSE: LH) reported fourth-quarter 2024 adjusted earnings per share of $3.45, up from $3.30 a year ago, beating the consensus of $3.39.
Sales increased 9.8% year-over-year to $3.33 billion, almost in line with the consensus of $3.31 billion.
The increase was due to organic revenue growth of 5.4%, acquisitions, net of divestitures of 4%, and foreign currency translation of 0.3%.
“In 2024, Labcorp delivered exceptional results driven by both organic and inorganic growth,” said Adam Schechter, chairman and CEO of Labcorp…Additionally, we strengthened our presence in key high growth areas including oncology, women’s health, neurology and autoimmune disease. In 2025, we are positioned to deliver strong growth and margin expansion across both Diagnostics Laboratories and Biopharma Laboratory Services…”
Also Read: Donald Trump’s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare
Adjusted operating income for the quarter was $423.2 million, or 12.7% of revenue, compared to $394.9 million, or 13%, in the fourth quarter.
William Blair analyst Andrew F. Brackmann writes, “We continue to believe the underlying business at Labcorp is on solid footing, as the diagnostics segment benefits from favorable macro tailwinds and the BLS segment sees solid growth in central labs (albeit decelerating off tough comps) and early development returns to growth.”
This positions the stock well for 2025, with stable guidance and potential for gains if the company’s momentum continues.
William Blair reiterates the Outperform rating.
Guidance: LabCorp expects 2025 adjusted EPS of 15.60-$16.40 versus the consensus of $16.0. It expects 2025 sales of $13.9 billion-$14.1 billion versus consensus Of $13.8 billion.
The guidance includes 2025 Diagnostics Laboratories sales growth of 6.5%- 7.7% and Biopharma Laboratory Services sales growth of 3.0%- 5.0%.
Price Action: Laboratory stock is down 0.92% at $247.68 at the last check on Thursday.
Read Next:
Photo by Gorodenkoff via Shutterstock
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.